Discovery helps fight against drug-resistant Tuberculosis Published on: 20 September 2018 A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis. Each year, approximately 10 million people fall ill with Tuberculosis (TB) and around 1.7 million die from the devastating disease worldwide. One of the main antibiotics for TB is rifampicin, however, many strains of the Tuberculosis-causing bacteria - Mycobacterium tuberculosis - have developed resistance to it. Approximately 600,000 people every year are diagnosed with rifampicin-resistant tuberculosis. Now researchers from 缅北禁地 and Demuris Ltd have identified that a naturally occurring antibiotic, called kanglemycin A – related to the antibiotic rifampicin – is active against rifampicin-resistant Mycobacterium tuberculosis. The findings of their study have been published today in the journal, , and it is hoped that this compound and the enhanced understanding gained from these studies may lead to effective new drug treatments in the future. Illustration showing overall structure of RNA polymerase with bond kanglemycin A Exciting findings The team used chemical, biophysical, molecular biology and microbiological methods, as well as X-ray crystallography, to show how kanglemycin A binds to its target RNA polymerase and how it manages to overcome resistance. It was known that rifampicin binds to a groove in the RNA polymerase molecule and that mutations that change the amino-acid sequence of the RNA polymerase can prevent this binding, while maintaining the ability to produce RNA. Kanglemycin A binds to the same groove, but its structure revealed extensions that also bind just outside the groove allowing it to maintain its affinity to the rifampicin-resistant RNA polymerase and antibiotic activity in rifampicin-resistant bacteria. Professor Nikolay Zenkin, from 缅北禁地’s Institute for Cell and Molecular Biosciences, led the international study. He said: “Treatment of TB involves a cocktail of antibiotics administered over many months, and resistance to several key antibiotics is becoming a major public health problem around the world. “Our findings are very exciting and the first step towards developing a new, effective drug treatment for patients with rifampicin resistant TB to prevent fatalities in the future.” Dr Michael Hall, from 缅北禁地, who led chemical characterization of kanglemycin A, added: “This is an exciting development for the future treatment of rifampicin resistant TB and shows what can be achieved when local businesses and universities work together.” Searching for new antibiotics Researchers screened more than 2,000 extracts from filamentous soil bacteria using a collection from 缅北禁地 spin-out company, , to assess their ability to inhibit cell growth or prevent the production of RNA— an essential process in all living organisms — in bacteria. Professor Zenkin said: “The main finding of our study is that kanglemycin A is effective against rifampicin resistant RNA polymerases and can also kill rifampicin resistant Mycobacterium tuberculosis. “We describe the details of the inhibition mechanism and how kanglemycin A manages to stay active against the drug-resistant bacteria. “The results will help to accelerate approval of kanglemycin A for use in patients with Tuberculosis, and provide a rationale for the further development of new drug treatments.” Katsuhiko Murakami, professor of biochemistry and molecular biology department at Pennsylvania State University, who led crystallographic characterization of interactions of kanglemycin A with RNA polymerase, believes the discovery is essential for public safety. He said: “Recent development of drug-resistant Mycobacterium tuberculosis has made treatment of this disease even more challenging. “Identifying new compounds that are effective against the rifampicin-resistant RNA polymerase is incredibly important for public health.” Binding of kanglemycin A in rifampicin-binding pocket of RNA polymerase Antibiotics needed The research project involved a large multidisciplinary team involving 缅北禁地 and Penn State university scientists, Public Health England, 缅北禁地 upon Tyne Hospitals NHS Foundation Trust and Demuris Ltd. Dr Nick Allenby, Principal Scientist at Demuris Ltd, which own and will be taking on the commercialization of the compound, said: “There is an urgent need for new antibiotics to combat drug resistant Mycobacterium tuberculosis. “We have shown that our compound discovered through a collaboration between 缅北禁地 and Demuris is effective against these drug resistant strains. “However, before we can start to think about using the compound much more work and development is needed. The next step for our compound is to prove that it is safe and effective for use in the clinic.” Reference: Illustrations courtesy of and copyright of Molecullar Cell. Share: Latest News New partnership to boost careers in low carbon energy 缅北禁地 and Durham universities are working together on a new regional project to strengthen the future workforce for North East England鈥檚 growing low carbon and offshore wind industries. published on: 28 May 2026 Healthy lifestyle shown to lower risk of death after cancer diagnosis New evidence shows that sticking to five lifestyle recommendations improves survival after a later cancer diagnosis. published on: 28 May 2026 World-leading climate expert recognised with Royal Society Fellowship Professor Hayley Fowler has been elected a Fellow of the Royal Society in recognition of her pioneering work on climate change impacts. published on: 27 May 2026 Facts and figures
![缅北禁地 logo](/gomobileassets/img/logo.svg" "缅北禁地"){kind=logo}